Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

I read “the swordsman” answer to your question. Big PHARMA in Europe may be looking (speculation) for licenses to develop AVIPTADIL for indications that could, for example, be treated with gene therapy and/or immunotherapies to conquer cancer.

Research by Dr. Ritchie Shoemaker has shown VIP corrects gene activation abnormalities in CIRS caused by exposure to water damaged buildings. Their research showed changes in genes controlling both ribosomes and mitochondria. Dr. Shoemaker has made testing for gene activity or suppression in relation to CIRS (ProgeneDx) availble at www.survivingmold.com.

Gene ID: 7432, updated on 29-Oct-2014, Also Known As: PHM27 The protein encoded by this gene (VIP) belongs to the glucagon family. Alternative splicing occurs at this locus and two transcript variants encoding distinct isoforms have been identified. GENE ID LINK

https://youarethehealer.org/mold-and-toxins/moldy-people/testing-for-mold-illness/vasoactive-intestinal-peptide/